🚀 VC round data is live in beta, check it out!
Evaxion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Evaxion and similar public comparables like Pluri, INmune Bio, Radiopharm Theranostics, Sprint Bioscience and more.
Evaxion Overview
About Evaxion
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options.
Founded
2008
HQ
Employees
46
Website
Sectors
Financials (LTM)
EV
$19M
Evaxion Financials
Evaxion reported last 12-month revenue of $7M.
In the same LTM period, Evaxion generated $7M in gross profit and had net loss of ($9M).
Revenue (LTM)
Evaxion P&L
In the most recent fiscal year, Evaxion reported revenue of $8M and EBITDA of ($7M).
Evaxion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | $7M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (95%) | XXX | XXX | XXX |
| EBIT Margin | (149%) | XXX | (122%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | (133%) | XXX | (102%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Evaxion Stock Performance
Evaxion has current market cap of $34M, and enterprise value of $19M.
Market Cap Evolution
Evaxion's stock price is $4.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19M | $34M | 2.2% | XXX | XXX | XXX | $-0.92 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEvaxion Valuation Multiples
Evaxion trades at 2.7x EV/Revenue multiple, and (2.6x) EV/EBITDA.
EV / Revenue (LTM)
Evaxion Financial Valuation Multiples
As of April 10, 2026, Evaxion has market cap of $34M and EV of $19M.
Equity research analysts estimate Evaxion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Evaxion has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34M | XXX | $34M | XXX | XXX | XXX |
| EV (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.6x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | — | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Evaxion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Evaxion Margins & Growth Rates
Evaxion's revenue in the last 12 month grew by 45%.
Evaxion's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Evaxion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 45% | XXX | (30%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (95%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (27%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 97% | XXX | 90% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 147% | XXX | 133% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 223% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Evaxion Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pluri | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sprint Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Evaxion M&A Activity
Evaxion acquired XXX companies to date.
Last acquisition by Evaxion was on XXXXXXXX, XXXXX. Evaxion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Evaxion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEvaxion Investment Activity
Evaxion invested in XXX companies to date.
Evaxion made its latest investment on XXXXXXXX, XXXXX. Evaxion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Evaxion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Evaxion
| When was Evaxion founded? | Evaxion was founded in 2008. |
| Where is Evaxion headquartered? | Evaxion is headquartered in Denmark. |
| How many employees does Evaxion have? | As of today, Evaxion has over 46 employees. |
| Who is the CEO of Evaxion? | Evaxion's CEO is Birgitte Rono. |
| Is Evaxion publicly listed? | Yes, Evaxion is a public company listed on Nasdaq. |
| What is the stock symbol of Evaxion? | Evaxion trades under EVAX ticker. |
| When did Evaxion go public? | Evaxion went public in 2021. |
| Who are competitors of Evaxion? | Evaxion main competitors are Pluri, INmune Bio, Radiopharm Theranostics, Sprint Bioscience. |
| What is the current market cap of Evaxion? | Evaxion's current market cap is $34M. |
| What is the current revenue of Evaxion? | Evaxion's last 12 months revenue is $7M. |
| What is the current revenue growth of Evaxion? | Evaxion revenue growth (NTM/LTM) is 45%. |
| What is the current EV/Revenue multiple of Evaxion? | Current revenue multiple of Evaxion is 2.7x. |
| Is Evaxion profitable? | No, Evaxion is not profitable. |
| What is the current net income of Evaxion? | Evaxion's last 12 months net income is ($9M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.